Cost advantages concentrated in higher OOP tiers: only 15% of all prescriptions were cheaper, but MCCPDC undercut insurance for ~82% of fills when OOP exceeded $15. Therapeutic areas with frequent ...

Swarup Kumar, MD, discusses how bispecific antibodies are pushing myeloma cure rates to 40%—and what clinicians must know ...

Formal adoption of PMOS replaces a cyst-centric label with terminology capturing endocrine, metabolic, and ovarian ...

Datopotamab deruxtecan is now a first-line targeted therapy for immunotherapy-ineligible metastatic TNBC, addressing the ~70% ...

Retatrutide met primary and key secondary endpoints in a 2339-participant, randomized, double-blind, placebo-controlled phase 3 trial, demonstrating clinically meaningful weight reduction across 4, 9, ...

Identification of fibroids on ultrasound can prematurely close evaluation, despite frequent co-existence and a ...

Young men and minority patients with early-onset CRC in urban areas face higher CVD death risk, challenging assumptions about ...

USPSTF recommendations have statutory coverage implications under the ACA, mandating no-cost coverage for graded preventive services and directly shaping access to mammography, colorectal screening, ...

The heart failure (HF) treatment landscape continues to evolve rapidly in 2026, with emerging evidence pointing toward a ...

Simple FNI labs pinpoint high‑mortality MASLD fibrosis in type 2 diabetes, challenging FIB‑4 and sharpening MASH liver ...

Reproductive-care access remains unsettled as mifepristone telehealth/mail distribution is temporarily protected by the ...